中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2014年
30期
44-45,47
,共3页
王巧燕%鲁淑谨%牟英峰%肖成华
王巧燕%魯淑謹%牟英峰%肖成華
왕교연%로숙근%모영봉%초성화
泮托拉唑%脑梗死%奥美拉唑%氯吡格雷%疗效评定
泮託拉唑%腦梗死%奧美拉唑%氯吡格雷%療效評定
반탁랍서%뇌경사%오미랍서%록필격뢰%료효평정
Pantoprazole%Infarction%Omeprazole%Clopidogrel%Efifcacy evaluation
目的:比较中国徐州地区汉族人群泮托拉唑+氯吡格雷+拜阿司匹林与奥美拉唑+氯吡格雷+拜阿司匹林治疗急性脑梗死的疗效差异,初步探讨泮托拉唑对氯吡格雷治疗急性脑梗死疗效的影响。方法选取400例发病3d内的急性脑梗死患者(均常规予氯吡格雷75mg和阿司匹林200mg口服),随机分为奥美拉唑组(n=200,加用奥美拉唑40mg/d,静脉用药)和泮托拉唑组(n=200,加用泮托拉唑60mg/d,静脉用药),分别于入院时、治疗后14d对其进行美国国立卫生研究院卒中量表(NIHSS)评分,并在治疗14d时对患者进行疗效评价。数据处理采用SPSS13.0软件包进行统计学分析。结果两组患者入院时的一般资料、NIHSS评分比较无明显差异(P均<0.05);治疗后两组患者的NIHSS评分均低于入院时,两组NIHSS评分比较显示泮托拉唑组低于奥美拉唑组(P<0.05),使用泮托拉唑组的疗效高于使用奥美拉唑组(P均<0.05)。结论泮托拉唑对氯吡格雷治疗急性脑梗死疗效的影响小于奥美拉唑,临床治疗急性脑梗死可优先选用泮托拉唑。
目的:比較中國徐州地區漢族人群泮託拉唑+氯吡格雷+拜阿司匹林與奧美拉唑+氯吡格雷+拜阿司匹林治療急性腦梗死的療效差異,初步探討泮託拉唑對氯吡格雷治療急性腦梗死療效的影響。方法選取400例髮病3d內的急性腦梗死患者(均常規予氯吡格雷75mg和阿司匹林200mg口服),隨機分為奧美拉唑組(n=200,加用奧美拉唑40mg/d,靜脈用藥)和泮託拉唑組(n=200,加用泮託拉唑60mg/d,靜脈用藥),分彆于入院時、治療後14d對其進行美國國立衛生研究院卒中量錶(NIHSS)評分,併在治療14d時對患者進行療效評價。數據處理採用SPSS13.0軟件包進行統計學分析。結果兩組患者入院時的一般資料、NIHSS評分比較無明顯差異(P均<0.05);治療後兩組患者的NIHSS評分均低于入院時,兩組NIHSS評分比較顯示泮託拉唑組低于奧美拉唑組(P<0.05),使用泮託拉唑組的療效高于使用奧美拉唑組(P均<0.05)。結論泮託拉唑對氯吡格雷治療急性腦梗死療效的影響小于奧美拉唑,臨床治療急性腦梗死可優先選用泮託拉唑。
목적:비교중국서주지구한족인군반탁랍서+록필격뢰+배아사필림여오미랍서+록필격뢰+배아사필림치료급성뇌경사적료효차이,초보탐토반탁랍서대록필격뢰치료급성뇌경사료효적영향。방법선취400례발병3d내적급성뇌경사환자(균상규여록필격뢰75mg화아사필림200mg구복),수궤분위오미랍서조(n=200,가용오미랍서40mg/d,정맥용약)화반탁랍서조(n=200,가용반탁랍서60mg/d,정맥용약),분별우입원시、치료후14d대기진행미국국립위생연구원졸중량표(NIHSS)평분,병재치료14d시대환자진행료효평개。수거처리채용SPSS13.0연건포진행통계학분석。결과량조환자입원시적일반자료、NIHSS평분비교무명현차이(P균<0.05);치료후량조환자적NIHSS평분균저우입원시,량조NIHSS평분비교현시반탁랍서조저우오미랍서조(P<0.05),사용반탁랍서조적료효고우사용오미랍서조(P균<0.05)。결론반탁랍서대록필격뢰치료급성뇌경사료효적영향소우오미랍서,림상치료급성뇌경사가우선선용반탁랍서。
Objective?To?compare?the?clinical?effects?of?pantoprazole?and?omeprazole?on?the?antiplatelet?therapy?of?clopidogrel?combined?with?aspirin?in?patients?of?acute?cerebral?infarction?lived?in?Xuzhou?China;?and?to?investigate?the?effects?of?pantoprazole?on?the?antiplatelet?therapy?of??clopidogrel??in?patients??of??acute??cerebral??infarction.?Methods?The?400?cases?of?acute?cerebral?infarction?received?the?conservative?therapy?were?randomized?for?dual?antiplatelet therapy of aspirin and clopidogrel associated with either pantoprasole 60 mg/day(Pantoprazole group)or omeprasole 40 mg/day(Omeprazole group)respectively,n=200?in?each?group.All?the?subjects?received?the?NIHSS?score?respectively?on?admission?and?at?the?time?of?14?days?after?starting?treatment, and received efifcacy evaluation at the time of two weeks after starting treatment. Data processing uses SPSS13.0 for the statistical analysis. Results There is no signiifcant difference (both P<0.05)in?the?general?information?and?NIHSS?score?of?two?groups?on?admission;?and?the?two?groups,?NIHSS?score?got?at?the?time?of?two?weeks?after?starting?treatment?were?lower?than?at?the?time?on?admission?NIHSS?score;?and?the?pantoprazole?group,s?score?were?lower than omeprazole groups(P<0.05). The clinical effects of pantoprazole group were better than omeprazole groups(P<0.05).Conclusion?The?clinical?effects?of?pantoprazole?on?the?antiplatelet?therapy?of??clopidogrel?in?patients?of?acute?cerebral?infarction?is?less?than?omeprazole,and?the?clinical?treatment?of?acute?cerebral?infarction?can?give?preference?to?pantoprazole.